In the Korean clinical setting, where SGLT2 inhibitors have recently been approved as standard therapy for heart failure and chronic kidney disease, our study contributes additional evidence for these expanded indications and helps reinforce their role in national treatment guidelines. This evidence concerns the gene SLC5A2 and chronic kidney disease.